
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to ALX Oncology Holdings’ (NASDAQ:ALXO) Evorpacept for the treatment of patients with acute myeloid leukemia (AML).
Evorpacept in combination with venetoclax and azacitidine is being evaluated in the Phase 1/2 ASPEN-05 study in patients with previously untreated AML who are not candidates for intensive induction therapy or with relapsed/refractory AML.